胃旁路术与袖状胃切除术对2型糖尿病缓解的随机对照试验
Oseberg研究是一项单中心、三盲随机试验,纳入109例肥胖合并2型糖尿病患者,比较胃旁路术与袖状胃切除术。
要点
- 胃旁路术在术后1年糖尿病完全缓解率上优于袖状胃切除术。
- 两种手术对β细胞功能(处置指数)的改善效果相似。
- 胃旁路术可作为肥胖合并2型糖尿病患者的优先术式选择。
核心结论
- 胃旁路术在术后1年2型糖尿病缓解方面优于袖状胃切除术,且两种术式对β细胞功能的有益影响相似。
研究设计与样本
- 单中心、三盲、随机对照试验,在挪威Vestfold医院信托进行,纳入109例肥胖合并2型糖尿病患者,随机分配至胃旁路术(n=54)或袖状胃切除术(n=55)。
主要发现
- 胃旁路术组54例中10例出现早期并发症,53例中17例出现晚期副作用;袖状胃切除术组55例中8例出现早期并发症,54例中22例出现晚期副作用。
- 两组均无死亡病例。
临床怎么用
- 对于肥胖合并2型糖尿病患者,胃旁路术可作为优先选择的减重手术术式,以提高糖尿病缓解率。
局限性
- 研究为单中心设计,样本量较小(109例),随访时间仅1年,可能限制结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with obesity and type 2 diabetes, weight loss improves insulin sensitivity and β-cell function, and can induce remission of diabetes. The comparative efficacy of various bariatric procedures for the remission of type 2 diabetes has not been fully elucidated. We aimed to compare the effects of the two most common bariatric procedures, gastric bypass and sleeve gastrectomy, on remission of diabetes and β-cell function. METHODS: We conducted a single-centre, triple-blind, randomised trial at Vestfold Hospital Trust (Tønsberg, Norway), in which patients (aged ≥18 years) with type 2 diabetes and obesity were randomly assigned (1:1) to receive gastric bypass or sleeve gastrectomy (the Oseberg study). Randomisation was performed with a computerised random number generator and a block size of 10. Treatment allocation was masked from participants, study personnel, and outcome assessors and was concealed with sealed opaque envelopes. Surgeons used identical skin incisions during both surgeries and were not involved in patient follow-up. The primary clinical outcome was the proportion of participants with complete remission of type 2 diabetes (HbA1c of ≤6·0% [42 mmol/mol] without the use of glucose-lowering medication) at 1 year after surgery. The primary physiological outcome was disposition index (a measure of β-cell function) at 1 year after surgery, as assessed by an intravenous glucose tolerance test. Primary outcomes were analysed in the intention-to-treat and per-protocol populations. This trial is ongoing and closed to recruitment, and is registered with ClinicalTrials.gov, NCT01778738. FINDINGS: Between Oct 15, 2012, and Sept 1, 2017, 1305 patients who were preparing for bariatric surgery were screened, of whom 319 consecutive patients with type 2 diabetes were assessed for eligibility. 109 patients were enrolled and randomly assigned to gastric bypass (n=54) or sleeve gastrectomy (n=55). 107 (98%) of 109 patients completed 1-year follow-up, with one patient in each group withdrawing after surgery (per-protocol population). In the intention-to-treat population, diabetes remission rates were higher in the gastric bypass group than in the sleeve gastrectomy group (risk difference 27% [95% CI 10 to 44]; relative risk [RR] 1·57 [1·14 to 2·16], p=0·0054); results were similar in the per-protocol population (risk difference 27% [95% CI 10 to 45]; RR 1·57 [1·14 to 2·15], p=0·0036). In the intention-to-treat population, disposition index increased in both groups (between-group difference 55 [-111 to 220], p=0·52); results were similar in the per-protocol population (between-group difference 21 [-214 to 256], p=0.86). In the gastric bypass group, ten of 54 participants had early complications and 17 of 53 had late side-effects. In the sleeve gastrectomy group, eight of 55 participants had early complications and 22 of 54 had late side-effects. No deaths occurred in either group. INTERPRETATION: Gastric bypass was found to be superior to sleeve gastrectomy for remission of type 2 diabetes at 1 year after surgery, and the two procedures had a similar beneficial effect on β-cell function. The use of gastric bypass as the preferred bariatric procedure for patients with obesity and type 2 diabetes could improve diabetes care and reduce related societal costs. FUNDING: Morbid Obesity Centre, Vestfold Hospital Trust.
引用
- Hofsø D, Fatima F, Borgeraas H, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2019. PMID: 31678062. doi:10.1016/S2213-8587(19)30344-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。